Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
McKesson
Express Scripts
Dow

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,977,077

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,977,077 protect, and when does it expire?

Patent 6,977,077 protects FORTEO and is included in one NDA.

This patent has sixty-six patent family members in thirty-four countries.

Summary for Patent: 6,977,077
Title: Method of increasing bone toughness and stiffness and reducing fractures
Abstract:The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Hock; Janet M. (Indianapolis, IN), Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/647,278
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,977,077
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,977,077

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes   Start Trial   Start Trial A METHOD OF TREATING OSTEOPOROSIS   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No   Start Trial   Start Trial FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,977,077

PCT Information
PCT FiledAugust 19, 1999PCT Application Number:PCT/US99/18961
PCT Publication Date:March 02, 2000PCT Publication Number: WO00/10596

International Family Members for US Patent 6,977,077

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033639   Start Trial
Austria 231000   Start Trial
Australia 5575099   Start Trial
Australia 746277   Start Trial
Brazil 9909445   Start Trial
Canada 2325371   Start Trial
China 1205997   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
AstraZeneca
McKesson
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.